SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-esophageal reflux disease: a systematic review. Gut 2005; 54: 71017.
  • 2
    Camilleri M, Dubois D, Coulie B, Jones M, Kahrilas PJ, Rentz AM, Sonnenberg A, Stanghellini V, Stewart WF, Tack J, Talley NJ, Whitehead W, Revicki DA. Prevalence and socio-economic impact of upper gastro-intestinal disorders in the United States: results of the US Upper Gastrointestinal Study. Clin Gastroenterol Hepatol 2005; 3: 54352.
  • 3
    Wong BC, Kinoshita Y. Systematic review on epidemiology of gastro-esophageal reflux disease in Asia. Clin Gastroenterol Hepatol 2006; 4: 398407.
  • 4
    Revicki DA, Wood M, Maton PN, Sorensen S. The impact of gastro-esophageal reflux disease on health-related quality of life. Am J Med 1998; 104: 2528.
  • 5
    Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastro-esophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340: 82531.
  • 6
    Avidan B, Sonnenberg A, Schnell TG, Chejfec G, Metz A, Sontag SJ. Hiatal hernia size, Barrett's length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma. Am J Gastroenterol 2002; 97: 19306.
    Direct Link:
  • 7
    Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastro-esophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112: 1798810.
  • 8
    Khan M, Santana J, Donnellan C, Preston C, Moayyedi P. Medical treatments in the short term management of reflux esophagitis. Cochrane Database Syst Rev 2007; (2): CD003244.
  • 9
    DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastro-esophageal reflux disease. Am J Gastroenterol 2005; 100: 190200.
    Direct Link:
  • 10
    Kahrilas PJ, Shaheen NJ, Vaezi MF, Hiltz SW, Black E, Modlin IM, Johnson SP, Allen J, Brill JV. American Gastroenterological Association Medical Position Statement on the management of gastro-esophageal reflux disease. Gastroenterology 2008; 135: 138391, 1391 e1–5.
  • 11
    Fock KM, Talley NJ, Fass R, Goh KL, Katelaris P, Hunt R, Hongo M, Ang TL, Holtmann G, Nandurkar S, Lin SR, Wong BC, Chan FK, Rani AA, Bak YT, Sollano J, Ho KY, Manatsathit S. Asia-Pacific consensus on the management of gastro-esophageal reflux disease: update. J Gastroenterol Hepatol 2008; 23: 822.
  • 12
    Carlsson R, Dent J, Watts R, Riley S, Sheikh R, Hatlebakk J, Haug K, De Groot G, Van Oudvorst A, Dalvag A, Junghard O, Wiklund I. Gastro-esophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol 1998; 10: 11924.
  • 13
    Inadomi JM, McIntyre L, Bernard L, Fendrick AM. Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs. Am J Gastroenterol 2003; 98: 19404.
    Direct Link:
  • 14
    Dean BB, Gano AD Jr, Knight K, Ofman JJ, Fass R. Effectiveness of proton pump inhibitors in non-erosive reflux disease. Clin Gastroenterol Hepatol 2004; 2: 65664.
  • 15
    Fass R, Shapiro M, Dekel R, Sewell J. Systematic review: proton-pump inhibitor failure in gastro-esophageal reflux disease – where next? Aliment Pharmacol Ther 2005; 22: 7994.
  • 16
    Ruth M, Hamelin B, Rohss K, Lundell L. The effect of mosapride, a novel prokinetic, on acid reflux variables in patients with gastro-esophageal reflux disease. Aliment Pharmacol Ther 1998; 12: 3540.
  • 17
    Ruth M, Finizia C, Cange L, Lundell L. The effect of mosapride on esophageal motor function and acid reflux in patients with gastro-esophageal reflux disease. Eur J Gastroenterol Hepatol 2003; 15: 111521.
  • 18
    Cho YK, Choi MG, Han HW, Park JM, Oh JH, Jeong JJ, Cho YS, Lee IS, Kim SW, Choi KY, Chung IS. The effect of mosapride on esophageal motility and bolus transit in asymptomatic volunteers. J Clin Gastroenterol 2006; 40: 28692.
  • 19
    Vigneri S, Termini R, Leandro G, Badalamenti S, Pantalena M, Savarino V, Di Mario F, Battaglia G, Mela GS, Pilotto A. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 1995; 333: 110610.
  • 20
    Madan K, Ahuja V, Kashyap PC, Sharma MP. Comparison of efficacy of pantoprazole alone versus pantoprazole plus mosapride in therapy of gastro-esophageal reflux disease: a randomized trial. Dis Esophagus 2004; 17: 2748.
  • 21
    Miyamoto M, Haruma K, Takeuchi K, Kuwabara M. Frequency scale for symptoms of gastroesophageal reflux disease predicts the need for addition of pro-kinetics to proton pump inhibitor therapy. J Gastroenterol Hepatol 2008; 23: 74651.
  • 22
    Lundell LR, Dent J, Bennett JR, Blum AL, Armstrong D, Galmiche JP, Johnson F, Hongo M, Richter JE, Spechler SJ, Tytgat GN, Wallin L. Endoscopic assessment of esophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999; 45: 17280.
  • 23
    Kusano M, Shimoyama Y, Sugimoto S, Kawamura O, Maeda M, Minashi K, Kuribayashi S, Higuchi T, Zai H, Ino K, Horikoshi T, Sugiyama T, Toki M, Ohwada T, Mori M. Development and evaluation of FSSG: frequency scale for the symptoms of GERD. J Gastroenterol 2004; 39: 88891.
  • 24
    Oridate N, Takeda H, Mesuda Y, Nishizawa N, Furuta Y, Asaka M, Fukuda S. Evaluation of upper abdominal symptoms using the Frequency Scale for the Symptoms of Gastroesophageal Reflux Disease in patients with laryngo-pharyngeal reflux symptoms. J Gastroenterol 2008; 43: 51923.
  • 25
    Baldi F, Bianchi Porro G, Dobrilla G, Iascone C, Lobello R, Marzio L, Sabbatini F, Tittobello A, Verme G. Cisapride versus placebo in reflux esophagitis: a multi-center double-blind trial. J Clin Gastroenterol 1988; 10: 6148.
  • 26
    Richter JE. Efficacy of cisapride on symptoms and healing of gastro-esophageal reflux disease: a review. Scand J Gastroenterol Suppl 1989; 165: 1927, discussion 27–8.
  • 27
    Ceccatelli P, Janssens J, Vantrappen G, Cucchiara S. Cisapride restores the decreased lower esophageal sphincter pressure in reflux patients. Gut 1988; 29: 6315.
  • 28
    Wong WM, Lai KC, Hui WM, Lam KF, Huang JQ, Hu WH, Wong NY, Lam CL, Xia HH, Chan AO, Lam SK, Wong BC. Double-blind, randomized controlled study to assess the effects of lansoprazole 30 mg and lansoprazole 15 mg on 24-h esophageal and intra-gastric pH in Chinese subjects with gastro-esophageal reflux disease. Aliment Pharmacol Ther 2004; 19: 45562.
  • 29
    Mulder CJ, Westerveld BD, Smit JM, Oudkerk Pool M, Otten MH, Tan TG, Van Milligen de Wit AW, De Groot GH. A double-blind, randomized comparison of omeprazole Multiple Unit Pellet System (MUPS) 20 mg, lansoprazole 30 mg and pantoprazole 40 mg in symptomatic reflux oesophagitis followed by 3 months of omeprazole MUPS maintenance treatment: a Dutch multicentre trial. Eur J Gastroenterol Hepatol 2002; 14: 64956.
  • 30
    Jensen MP, Karoly P. Motivation and expectancy factors in symptom perception: a laboratory study of the placebo effect. Psychosom Med 1991; 53: 14452.
  • 31
    DeVault KR. Review article: the role of acid suppression in patients with non-erosive reflux disease or functional heartburn. Aliment Pharmacol Ther 2006; 23 (Suppl. 1):339.
  • 32
    Frazzoni M, De Micheli E, Zentilin P, Savarino V. Patho-physiological characteristics of patients with non-erosive reflux disease differ from those of patients with functional heartburn. Aliment Pharmacol Ther 2004; 20: 818.
  • 33
    Savarino E, Pohl D, Zentilin P, Dulbecco P, Sammito G, Sconfienza L, Vigneri S, Camerini G, Tutuian R, Savarino V. Functional heartburn has more in common with functional dyspepsia than with non-erosive reflux disease. Gut 2009; 58: 118591.